Education
About Us
Working with TipRanks
Follow Us
Knight Therapeutics (TSE:GUD)
TSX:GUD
Total Valuation
Knight Therapeutics has a market cap or net worth of C$587.22M. The enterprise value is C$614.31M.
Market CapC$587.22M
Enterprise ValueC$614.31M
Share Statistics
Knight Therapeutics has 99,192,345 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding99,192,345
Owned by Insiders30.25%
Owned by Institutions0.09%
Financial Efficiency
Knight Therapeutics’s return on equity (ROE) is <0.01 and return on invested capital (ROIC) is 0.85%.
Return on Equity (ROE)<0.01
Return on Assets (ROA)<0.01
Return on Invested Capital (ROIC)0.85%
Return on Capital Employed (ROCE)<0.01
Revenue Per Employee498.39K
Profits Per Employee5.81K
Employee Count745
Asset Turnover0.39
Inventory Turnover1.92
Valuation Ratios
The current PE Ratio of Knight Therapeutics is ―. Knight Therapeutics’s PEG ratio is -0.98.
PE Ratio―
PS Ratio1.45
PB Ratio0.68
Price to Fair Value0.68
Price to FCF112.22
Price to Operating Cash Flow16.41
PEG Ratio-0.98
Income Statement
In the last 12 months, Knight Therapeutics had revenue of 371.30M and earned 4.33M in profits. Earnings per share was 0.04.
Revenue371.30M
Gross Profit174.41M
Operating Income7.40M
Pretax Income2.05M
Net Income4.33M
EBITDA64.38M
Earnings Per Share (EPS)0.04
Cash Flow
In the last 12 months, operating cash flow was 35.95M and capital expenditures -30.31M, giving a free cash flow of 5.63M billion.
Operating Cash Flow35.95M
Free Cash Flow5.63M
Free Cash Flow per Share0.06
Dividends & Yields
Knight Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.26
52-Week Price Change3.86%
50-Day Moving Average6.01
200-Day Moving Average6.01
Relative Strength Index (RSI)49.17
Average Volume (3m)48.52K
Important Dates
Knight Therapeutics upcoming earnings date is Mar 19, 2026, Before Open (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 19, 2026
Ex-Dividend Date―
Financial Position
Knight Therapeutics as a current ratio of 3.57, with Debt / Equity ratio of 13.86%
Current Ratio3.57
Quick Ratio2.64
Debt to Market Cap0.08
Net Debt to EBITDA-0.48
Interest Coverage Ratio0.80
Taxes
In the past 12 months, Knight Therapeutics has paid -2.28M in taxes.
Income Tax-2.28M
Effective Tax Rate-1.11
Enterprise Valuation
Knight Therapeutics EV to EBITDA ratio is 7.90, with an EV/FCF ratio of 105.85.
EV to Sales1.37
EV to EBITDA7.90
EV to Free Cash Flow105.85
EV to Operating Cash Flow14.03
Balance Sheet
Knight Therapeutics has C$95.56M in cash and marketable securities with C$106.24M in debt, giving a net cash position of -C$10.68M billion.
Cash & Marketable SecuritiesC$95.56M
Total DebtC$106.24M
Net Cash-C$10.68M
Net Cash Per Share-C$0.11
Tangible Book Value Per ShareC$4.21
Margins
Gross margin is 38.76%, with operating margin of 1.99%, and net profit margin of 1.17%.
Gross Margin38.76%
Operating Margin1.99%
Pretax Margin0.55%
Net Profit Margin1.17%
EBITDA Margin17.34%
EBIT Margin3.04%
Analyst Forecast
The average price target for Knight Therapeutics is C$8.52, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetC$8.52
Price Target Upside43.94% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast18.70%
EPS Growth Forecast88.31%